Singapore markets close in 4 hours 2 minutes

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
3.8600+0.1100 (+2.93%)
At close: 03:11PM EST
Full screen
Previous close3.7500
Open3.9400
Bid3.8200 x N/A
Ask3.8600 x N/A
Day's range3.8200 - 3.9400
52-week range0.8000 - 4.8500
Volume1,170
Avg. volume24,269
Market cap82.577M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.2720
Earnings date07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.38
  • CNW Group

    Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the third quarter ended September 30, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.

  • CNW Group

    Eupraxia Pharmaceuticals Appoints Chief Business Officer

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed Paul Brennan to the role of Chief Business Officer ("CBO").

  • CNW Group

    Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic Esophagitis

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced the initiation of a Phase 2 trial of EP-104IAR in adult patients afflicted with eosinophilic esophagitis (EoE), a rare disease that restricts the ability to swallow food and greatly impacts quality of life.